MINI FUTURE LONG - NOVO-NORDISK B | Real-time Euronext Paris 03:37:26 2024-05-23 am EDT | ||
| 3.225 EUR | +4.03% |
|
| Current month | +14.60% | ||
| 1 month | +22.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 3.225 | +4.03% |
| 24-05-22 | 3.1 | -0.48% |
| 24-05-21 | 3.115 | +10.85% |
| 24-05-17 | 2.81 | -5.70% |
| 24-05-16 | 2.98 | -1.97% |
Real-time Euronext Paris
Last update May 23, 2024 at 03:37 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| Q05NB | |
| ISIN | NLBNPNL2P6O8 |
| Date issued | 2024-03-22 |
| Strike | 695.7 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.63 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.225 € |
|---|---|
| Lowest since issue | 1.85 € |
| Spread | 0.01 € |
| Spread % | 0.32% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
923
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.49%
- Stock Market
- Certificates
- Q05NB Certificat
